• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Milia

News
Article

The whitish lesions on the nose and chin of this neonate are milia-tiny keratinous inclusion cysts that occur mainly on and around the nose.

The whitish lesions on the nose and chin of this neonate are milia-tiny keratinous inclusion cysts that occur mainly on and around the nose. Up to 40% of full-term infants have milia, which usually disappear spontaneously within a few weeks to a few months.

Related Content
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD

Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD

Sydney Jennings
June 11th 2025
Article

RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Sydney Jennings
May 7th 2025
Podcast

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Upadacitinib Shows Real-World Efficacy in Bio-Naïve, Bio-Experienced Adults with Atopic Dermatitis in New Study

Upadacitinib Shows Real-World Efficacy in Bio-Naïve, Bio-Experienced Adults with Atopic Dermatitis in New Study

Sydney Jennings
June 9th 2025
Article

RAD 2025: Many adults achieved optimal treatment targets with upadacitinib after 6 months, regardless of prior biologic therapy, according to new late-breaking data.

/Gil Yosipovitch, MD Courtesy of Miller School of Medicine

Q&A: Managing Chronic Itch With Renowned Investigator Gil Yosipovitch, MD

Gil Yosipovitch, MD;Grace Halsey
June 9th 2025
Article

RAD 2025: World expert on the pathophysiology of itch Gil Yosipovitch, MD, answers questions on the disease of chronic itch and on the expanding options for targeted treatment.

Dupilumab Monotherapy Improves AD Severity and Pigmentation in People With Skin of Color

Dupilumab Monotherapy Improves AD Severity and Pigmentation in People With Skin of Color

Sydney Jennings
June 9th 2025
Article

Dupilumab monotherapy showed significant improvements in atopic dermatitis symptoms in patients with skin of color, according to late-breaking data presented at RAD 2025.

Nemolizumab Demonstrates Long-Term Efficacy, Safety in Interim Analysis of 2-Year ARCADIA Open Label Extension Study in Atopic Dermatitis / Jonathan Silverberg, MD, PhD, MPH

Long-Term Data on Nemolizumab Demonstrate Safety, Sustained Symptom Improvement in Patients With Atopic Dermatitis up to 2 Years

Grace Halsey
June 9th 2025
Article

RAD 2025: Adults and adolescents treated with nemolizumab experienced rapid onset of action and robust improvements in pruritis, sleep, and quality of life up to 2 years.

© 2025 MJH Life Sciences

All rights reserved.